关注
Amy L Carr
Amy L Carr
AdventHealth Orlando
在 adventhealth.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida
E Oliveira, A Parikh, A Lopez-Ruiz, M Carrilo, J Goldberg, M Cearras, ...
PloS one 16 (3), e0249038, 2021
1592021
Clinical Utility of Methicillin‐Resistant Staphylococcus aureus Nasal Screening for Antimicrobial Stewardship: A Review of Current Literature
AL Carr, MJ Daley, K Givens Merkel, DT Rose
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38 (12 …, 2018
592018
Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections
NC Warner, LA Bartelt, AM Lachiewicz, KM Tompkins, MB Miller, K Alby, ...
Clinical Infectious Diseases 73 (7), e1754-e1757, 2021
382021
Renin angiotensin aldosterone system antagonism in 2019 novel coronavirus acute lung injury
D Ventura, AL Carr, RD Davis, S Silvestry, L Bogar, N Raval, C Gries, ...
Open Forum Infectious Diseases 8 (10), ofab170, 2021
52021
1607. Dual therapy with aztreonam & ceftazidime/avibactam against multi-drug resistant Stenotrophomonas maltophilia on tricuspid valve endocarditis
J Alexander, A Carr, SB Minor, D Navas
Open Forum Infectious Diseases 7 (Suppl 1), S798, 2020
42020
Pharmacist-Driven Methicillin-Resistant S. aureus Polymerase Chain Reaction Testing for Pneumonia
V Marinucci, PR Louzon, AL Carr, J Hayes, A Lopez-Ruiz, J Sniffen
Annals of Pharmacotherapy 57 (5), 560-569, 2023
32023
Evaluating predictors of invasive candidiasis in patients with and without candidemia on micafungin
A Carr, P Colley, M Berhe, HL Nguyen
Baylor University Medical Center Proceedings 31 (1), 30-34, 2018
32018
666. Outcomes Using Cefiderocol for the Treatment of Acinetobacter baumannii Infections from the PROVE (Real-World Evidence) Study
S Marcella, E Kobic, AL Carr, B Georgiades, C Margiotta
Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 718, 2022
22022
1615. Isolation of Lytic Bacteriophages with Broad Host Range Activity Against Pseudomonas aeruginosa Strains Isolated from Respiratory Samples from Cystic Fibrosis Patients …
J Alexander, D Navas, M Flowers, A Charles, A Carr
Open Forum Infectious Diseases 7 (Suppl 1), S801, 2020
22020
2275. Novel therapeutic options for the treatment of multi-drug-resistant Achromobacter respiratory infections
T Canonica, S Thompson, A Carr, J Alexander, SB Minor
Open Forum Infectious Diseases 6 (Suppl 2), S779, 2019
22019
Risk factors for Candidemia as Compared with patients with negative blood cultures placed on empiric micafungin
A Carr, M Berhe
Open Forum Infectious Diseases 4 (Suppl 1), S79, 2017
22017
A Baker's Dozen of Top Antimicrobial Stewardship Intervention Publications in 2022
RK Barfield, ML Brown, B Albrecht, KE Barber, J Bouchard, AL Carr, ...
Open Forum Infectious Diseases 11 (3), ofad687, 2024
12024
Epidemiology and treatment of invasive Bartonella spp. infections in the United States
M Pizzuti, P Bailey, C Derrick, B Albrecht, AL Carr, EW Covington, ...
Infection, 1-8, 2024
12024
667. Real-world Experience of Cefiderocol with Pseudomonas aeruginosa in the PROVE (Retrospective Cefiderocol Chart Review) Study
S Marcella, AL Carr, E Kobic, S Nguyen, A Zhou
Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 719, 2022
12022
Analytical and clinical validation of direct detection of antimicrobial resistance markers by plasma microbial cell-free DNA sequencing
FC Christians, J Akhund-Zade, K Jarman, S Venkatasubrahmanyam, ...
Journal of Clinical Microbiology, e00425-24, 2024
2024
Trimethoprim/Sulfamethoxazole vs Minocycline for the Treatment of Nonurinary Monomicrobial Stenotrophomonas maltophilia Infections in Hospitalized Patients
EC Hevia, L Wooten, AL Carr
Annals of Pharmacotherapy 58 (7), 698-704, 2024
2024
528: A PHARMACIST-DRIVEN MRSA PCR ALGORITHM IN CRITICALLY ILL VS NON-CRITICALLY ILL PNEUMONIA PATIENTS
P Louzon, B North, V Marinucci, A Carr
Critical Care Medicine 52 (1), S237, 2024
2024
181. Impact of Rapid Diagnostic Technology on Patients with Candidemia
P Funderburk, AL Carr, JE Hayes
Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 259, 2022
2022
919. Let’s GO PO: Impact of Monthly Feedback on a Longitudinal Intravenous to Oral Antimicrobial Conversion Initiative
JE Hayes, AL Carr
Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 764, 2022
2022
925. Remdesperate for Stewardship: Impact of a Remdesivir Stewardship Strategy on the Care of Patients with COVID-19 Admitted to a Community Teaching Hospital
J Hayes, A Ghonim, L Wooten, J Sippel-Tompkins, V Herrera, AL Carr
Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 770, 2022
2022
系统目前无法执行此操作,请稍后再试。
文章 1–20